Fundz

Crinetics Pharmaceuticals

San Diego, United States · Biopharma, Biotechnology, Healthcare

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid

Key facts

Headquarters
San Diego, United States
Employees
393
Industries
Biopharma, Biotechnology, Healthcare
Website
crinetics.com
LinkedIn
Company page

Recent activity at Crinetics Pharmaceuticals

  • : SEC 8-K (2.01): On September 1, 2026, Crinetics Pharmaceuticals, Inc. completed the merger with Vertex Pharmaceuticals Incorporated following the terms set forth in the previously announced Agreement and Plan of Merger dated July 6, 2026. As a result of this transaction, Crinetics Pharmaceuticals has become a wholly owned subsidiary of Vertex Pharmaceuticals. The strategic implications of this merger could enhance Vertex's portfolio in the pharmaceutical sector, given Crinetics' innovative product pipeline. The merger was finalized on the closing date, ensuring an immediate transition in management and operational synergies.
  • : SEC 8-K (5.07): On August 28, 2026, Crinetics Pharmaceuticals, Inc. held a special meeting of shareholders to vote on proposals relating to a significant merger. The meeting saw 79,264,631 of the total 106,095,205 shares represented, reflecting active participation from shareholders. The record date for the meeting was July 27, 2026, which set the eligibility for voting. This event is crucial as it indicates shareholder approval on decisions likely impacting the future operations and strategy of Crinetics, especially concerning the planned merger detailed in the proxy statement filed on July 31, 2026.
  • : SEC 8-K (8.01):
  • : SEC 8-K (8.01): On August 12, 2026, the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act for the merger between Crinetics Pharmaceuticals, Inc. and Vertex Pharmaceuticals Incorporated expired, marking a significant step towards completing the merger. As of August 13, 2026, required approvals under antitrust laws in Austria, Germany, and Australia were obtained, paving the way for the merger to proceed, although the waiting period in Australia is set to expire on August 27, 2026. Importantly, the completion of the merger is contingent upon shareholder approval at a special meeting scheduled for August 28, 2026, with expectations for the merger to close in early September 2026. This transaction will result in Crinetics becoming a wholly-owned subsidiary of Vertex, which may enhance Vertex's portfolio in the pharmaceutical industry.
  • : SEC 8-K (5.02):
  • : SEC 8-K (1.01): On July 6, 2026, Crinetics Pharmaceuticals, Inc. entered into a Merger Agreement with Vertex Pharmaceuticals Incorporated and Clark Merger Sub, Inc. According to the agreement, Clark Merger Sub will merge into Crinetics, with Crinetics surviving as a wholly owned subsidiary of Vertex. Each share of Crinetics common stock will be converted into $85.00 per share in cash. The transaction includes conditions such as the approval from a majority of Crinetics' shareholders and necessary regulatory clearances. This merger signifies a strategic shift for Crinetics as it joins Vertex's broader portfolio, enhancing its market positioning.
  • : SEC 8-K (5.02): On April 10, 2026, Jeff Knight resigned as Chief Development and Operating Officer of Crinetics Pharmaceuticals, Inc. and entered into an Independent Consultant Agreement with the Company, effective the same day. Under this agreement, Mr. Knight will provide operational and clinical development services for one year, with compensation of $400 per hour for up to 20 hours per month. His unvested stock options will be forfeited upon resignation, while vested options can be exercised for three months post-Consulting Period. Additionally, Mr. Knight agreed to release any claims related to his departure, and the Company extended certain indemnification rights to him during the Consulting Period.
  • : SEC 8-K (5.02):
  • : SEC 8-K (4.01): On February 27, 2026, Crinetics Pharmaceuticals, Inc. dismissed BDO USA, P.C. as its independent registered public accounting firm. The decision was made by the Audit Committee of the Board of Directors. It's noted that BDO's reports on the financial statements for the fiscal years ended December 31, 2025, and 2024 were unmodified and did not contain any adverse opinions. This change could impact the company's financial reporting and investor perception. The effective date of this accountant dismissal is immediate as of the approval by the Audit Committee.
  • : SEC 8-K (2.02): On February 26, 2026, Crinetics Pharmaceuticals, Inc. reported its financial results for the period ended December 31, 2025. The filing includes a press release that outlines key financial metrics and insights into the company’s performance over the past year. The results include revenue figures, net income, and other significant financial indicators, providing shareholders and analysts with a comprehensive view of the company's current operational health and strategic direction. The financial data serves to inform future investment and operational decisions, reflecting Crinetics' ongoing developments in the pharmaceutical sector.

Crinetics Pharmaceuticals funding history

DateRoundAmount
Mar 2024Venture$350.0M
Feb 2018Venture$60.0M
Nov 2015Venture$18.0M

Leadership

  • Weston Ph.D, Director
  • Matthew Fust, Director
  • Jack Nielsen, Director
  • Wendell Ph.D, Director
  • Steve Ph.D, Director
  • Mason M.D., Director
  • Richard Ph.D, Executive Officer, Director
  • Tobin Schilke, Chief Financial Officer
  • Robert M. Cuddihy, Vice President
  • Marc Wilson, Executive Officer
  • Scott Struthers, Founder

Verified email and direct lines for Crinetics Pharmaceuticals’s decision-makers are on Fundz. See plans — or book a 15-minute walkthrough.

Employee benefit plans

Crinetics Pharmaceuticals files 3 employee benefit plans with the U.S. Department of Labor, including a retirement plan. The next plan year renews in Dec 2026.

Crinetics Pharmaceuticals in the news

Companies similar to Crinetics Pharmaceuticals

About Crinetics Pharmaceuticals: questions and answers

What does Crinetics Pharmaceuticals do?

Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on the discovery, development, and commercialization of novel therapeutics for endocrine diseases and endocrine-related tumors. Paltusotine, an investigational, first-in-class, oral somatostatin receptor type 2 (SST2) agonist, is in Phase 3 clinical development for acromegaly and Phase 2 clinical development for carcinoid

Where is Crinetics Pharmaceuticals headquartered?

Crinetics Pharmaceuticals is headquartered in San Diego, United States.

How many employees does Crinetics Pharmaceuticals have?

Crinetics Pharmaceuticals has about 393 employees.

Has Crinetics Pharmaceuticals raised funding?

Yes. Fundz has recorded 3 funding events for Crinetics Pharmaceuticals. The most recent, $350.0M, was in Mar 2024.

Who leads Crinetics Pharmaceuticals?

Robert M. Cuddihy is a Vice President at Crinetics Pharmaceuticals.

What is the latest news on Crinetics Pharmaceuticals?

On Sep 01, 2026, SEC 8-K (2.01): On September 1, 2026, Crinetics Pharmaceuticals, Inc. completed the merger with Vertex Pharmaceuticals Incorporated following the terms set forth in the previously announced Agreement and Plan of Merger dated July 6, 2026. As a result of this transaction, Crinetics Pharmaceuticals ha

Source: Fundz records from SEC filings, press releases and company announcements. How Fundz measures data accuracy

Fundz watches Crinetics Pharmaceuticals across 18 signal types, from funding and M&A to exec moves and hiring.

145 of these a day, filtered to the companies you pick, with the decision-maker attached.

5 screens from a live account. No signup.